News
Resources
Blog
Sites
H.R. 3 threatens access to medicines, future innovation and American jobs
By Gabby Migliara | May 4, 2021
In the last election, voters made clear that they want quality, affordable health coverage that works when they need it and lower out-of-pocket costs for medicines. And we can achieve those goals,...
Read More
New analysis finds stark difference in coverage of breast cancer medicines for seniors in the United States and England
By Nicole Longo | December 10, 2020
In the United States, seniors and people with disabilities enjoy broad coverage of physician-administered medicines under Medicare Part B because the program relies on market competition to...
Read More
No matter how you look at it, the Most Favored Nation rule is bad policy
By Nicole Longo | December 1, 2020
Last month, the administration released the “Most Favored Nation” (MFN) rule, which allows foreign governments to decide the value of Part B medicines, while also likely limiting seniors’ access...
Read More
Learning from history: How government price setting and other anti-innovation policies negatively impact biopharmaceutical R&D
By Nicole Longo | November 16, 2020
Today, America leads the world in medical innovation because of our unique research ecosystem, but that wasn’t always the case. A new paper from NDP Analytics, “Will US Leadership in...
Read More
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
By Andrew Powaleny | August 4, 2020
America’s biopharmaceutical companies are working around the clock to defeat COVID-19, a disease caused by a novel strain of the coronavirus. The biopharmaceutical industry continues to make...
Read More
Executive order threatens R&D when we need it most to fight COVID-19
By Nicole Longo | July 30, 2020
In case you missed it, President Trump recently signed executive orders that would implement sweeping changes to the biopharmaceutical industry. While his intention may have been to help Americans...
Read More
The continued imperative to protect U.S. innovation worldwide
By Chris Moore | April 29, 2020
The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are...
Read More
Three reasons the Administration should abandon its International Pricing Index proposal
By Nicole Longo | January 31, 2020
According to the Council of Economic Advisers, “Heavy-handed government intervention may reduce drug prices in the short term, but these savings are not worth the long-term cost of American...
Read More
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
By Guest Contributor | September 4, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Setting the record straight on international reference pricing
By Kevin Haninger | July 16, 2019
There’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
